Clinical Parkinsonism Related Disorders最新文献

{"title":"Mucuna beans administered through hydrogen-infused superheated steam in advanced Parkinson's disease","authors":"Ryuji Neshige,&nbsp;Shuichiro Neshige","doi":"10.1016/j.prdoa.2024.100252","DOIUrl":"https://doi.org/10.1016/j.prdoa.2024.100252","url":null,"abstract":"<div><p>This retrospective review on patients with Parkinson's disease, focusing on using mucuna beans (MB), its dosing, and administration methods. Two hundred patients taking 1–3 g of MP dissolved in hot water daily orally. Besides, MB administration via enema may be viable, especially when oral L-dopa efficacy is insufficient.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100252"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000239/pdfft?md5=97b83fa446a45b1c199dc1390659ce2b&pid=1-s2.0-S2590112524000239-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140551590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progressive supranuclear palsy phenotype as an atypical clinical presentation of Creutzfeldt-Jakob disease: A case report and review of the literature","authors":"Matteo Costanzo ,&nbsp;Flavia Aiello ,&nbsp;Anna Poleggi ,&nbsp;Pietro Li Voti ,&nbsp;Giovanni Fabbrini ,&nbsp;Daniele Belvisi","doi":"10.1016/j.prdoa.2024.100247","DOIUrl":"https://doi.org/10.1016/j.prdoa.2024.100247","url":null,"abstract":"<div><p>Creutzfeldt-Jakob disease (CJD) is a rare, rapidly progressive neurodegenerative disorder, characterized by the accumulation of abnormal prion proteins in the brain. While CJD has some typical clinical features, its presentation can be quite heterogeneous, particularly in the early stages of the disease, posing challenges in diagnosis. Atypical manifestations of CJD can mimic various neurodegenerative disorders, including atypical parkinsonisms. In this case report, we present an 81-year-old man who exhibited an atypical clinical presentation of sporadic CJD, initially resembling progressive supranuclear palsy (PSP). The patient presented with symmetric parkinsonism, postural instability, and ocular motor dysfunction, accompanied by rapid clinical deterioration. Alongside the case report, we also provide a review of the literature on atypical presentations of CJD as PSP, highlighting the importance of recognizing these manifestations in clinical practice.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100247"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000161/pdfft?md5=2accb256acc98b4f2c4ae1f5e4c832a5&pid=1-s2.0-S2590112524000161-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140051641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The potential role of chronic pain and the polytrauma clinical triad in predicting prodromal PD: A cross-sectional study of U.S. Veterans","authors":"Lee E. Neilson ,&nbsp;Nadir M. Balba ,&nbsp;Jonathan E. Elliott ,&nbsp;Gregory D. Scott ,&nbsp;Scott D. Mist ,&nbsp;Matthew P. Butler ,&nbsp;Mary M. Heinricher ,&nbsp;Miranda M. Lim","doi":"10.1016/j.prdoa.2024.100253","DOIUrl":"https://doi.org/10.1016/j.prdoa.2024.100253","url":null,"abstract":"<div><h3>Introduction</h3><p>The research criteria for prodromal Parkinson disease (pPD) depends on prospectively validated clinical inputs with large effect sizes and/or high prevalence. Neither traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), nor chronic pain are currently included in the calculator, despite recent evidence of association with pPD. These conditions are widely prevalent, co-occurring, and already known to confer risk of REM behavior disorder (RBD) and PD. Few studies have examined PD risk in the context of TBI and PTSD; none have examined chronic pain. This study aimed to measure the risk of pPD caused by TBI, PTSD, and chronic pain.</p></div><div><h3>Methods</h3><p>216 US Veterans were enrolled who had self-reported recurrent or persistent pain for at least three months. Of these, 44 met criteria for PTSD, 39 for TBI, and 41 for all three conditions. Several pain, sleep, affective, and trauma questionnaires were administered. Participants’ history of RBD was determined via self-report, with a subset undergoing confirmatory video polysomnography.</p></div><div><h3>Results</h3><p>A greater proportion of Veterans with chronic pain met criteria for RBD (36 % vs. 10 %) and pPD (18.0 % vs. 8.3 %) compared to controls. Proportions were increased in RBD (70 %) and pPD (27 %) when chronic pain co-occurred with TBI and PTSD. Partial effects were seen with just TBI or PTSD alone. When analyzed as continuous variables, polytrauma symptom severity correlated with pPD probability (r = 0.28, <em>P</em> = 0.03).</p></div><div><h3>Conclusion</h3><p>These data demonstrate the potential utility of chronic pain, TBI, and PTSD in the prediction of pPD, and the importance of trauma-related factors in the pathogenesis of PD.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100253"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000240/pdfft?md5=1782dc09624054d86644af86f9ee1983&pid=1-s2.0-S2590112524000240-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140641122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Movement disorder Deep brain stimulation Hybridization: Patient and caregiver outcomes","authors":"Nathan Esplin,&nbsp;Dorian Kusyk,&nbsp;Seung W Jeong,&nbsp;Shahed Elhamdani,&nbsp;Khaled Abdel Aziz,&nbsp;Amanda Webb,&nbsp;Cindy Angle,&nbsp;Donald Whiting,&nbsp;Nestor D. Tomycz","doi":"10.1016/j.prdoa.2024.100234","DOIUrl":"10.1016/j.prdoa.2024.100234","url":null,"abstract":"<div><h3>Background and Objectives</h3><p>Deep brain stimulation (DBS) is a well-established surgical treatment for certain movement disorders and involves the implantation of brain electrodes connected to implantable pulse generators (IPGs). As more device manufacturers have entered the market, some IPG technology has been designed to be compatible with brain electrodes from other manufacturers, which has facilitated the hybridization of implant technology. The aim of this study was to assess the benefits of hybridization of non-rechargeable, constant voltage IPGs to rechargeable, constant current IPGs.</p></div><div><h3>Methods</h3><p>A list of DBS movement disorder patients who had their non-rechargeable, constant voltage IPGs replaced with rechargeable, constant current IPGs from a different manufacturer was compiled. Structured surveys of these patients, and their caregivers when applicable, were undertaken to determine both patient and caregiver satisfaction in this DBS hybridization strategy.</p></div><div><h3>Results</h3><p>Eighteen patients met inclusion criteria and twelve patients or their caregivers completed the structured survey (67% response rate). Nine patients had Parkinson’s disease (75%), three had essential tremor (25%). Nine (75%) were converted from bilateral single-channel IPGs, and three (25%) were converted from a unilateral dual-channel IPGs. Overall, 92% of patients and caregivers surveyed reported improvement or no change in their symptoms, 92% reported a decrease or no change in their medication requirements, and 92% report they are satisfied or very satisfied with their IPG hybridization and would recommend the surgery to similar patients. There were no immediate surgical complications.</p></div><div><h3>Conclusion</h3><p>In this series of movement disorder DBS patients, surgery was safe and patient and caregiver satisfaction were high with a hybridization of non-rechargeable, constant voltage IPGs to rechargeable, constant current IPGs.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100234"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000033/pdfft?md5=43a1929caa2886be8101445aa9f2f19a&pid=1-s2.0-S2590112524000033-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139396170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The selfie sign in the diagnosis of functional tremor","authors":"Ekhlas Assaedi,&nbsp;Xin Xin Yu,&nbsp;Junaid Siddiqui,&nbsp;Umar A Shuaib","doi":"10.1016/j.prdoa.2024.100238","DOIUrl":"https://doi.org/10.1016/j.prdoa.2024.100238","url":null,"abstract":"<div><p>Functional tremor (FT) is the most common phenotype of functional movement disorders (FMD). Its diagnosis can often be challenging. While positive signs such as tremor variability, distractibility, and entrainment support a diagnosis of FT, these diagnostic clues may not always be present and can be challenging to assess. In this case series, we identify another examination technique which could be of value when assessing FT. In our Movement Disorders clinic, charts were retrospectively reviewed for relevant clinical information. Video examinations were conducted. Obtained videos were either synchronous, via the use of screen recording software during telehealth visits or asynchronous, from self-recorded home videos. In both settings, patients were instructed to self-record their tremor using their phone cameras. Three patients with FT or comorbid FT were identified as demonstrating a unique examination sign. Videos showed an improvement or suppression of the tremor when the phone was held by the affected hand. When compared to a patient with tremor-dominant Parkinson’s disease serving as a control, this “selfie sign” was not observed. These observations are preliminary and larger studies are needed to confirm the usefulness of the selfie sign in diagnosing FT. Patient-recorded videos of their tremor can be a convenient and practical way of evaluating suspected FT, especially when paroxysmal or variable symptoms limit the usefulness of classic signs often assessed in the clinic.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100238"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000070/pdfft?md5=6fbc27f7840c736a21debe86e769a9ff&pid=1-s2.0-S2590112524000070-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139653837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the layers of fatigue in Parkinson’s Disease: A comprehensive analysis of its prevalence and contributing factors","authors":"Filipe Sarmento ,&nbsp;Griffin Lamp ,&nbsp;Venkat Srikar Lavu ,&nbsp;Achyutha S. Madamangalam ,&nbsp;Jagan Mohan Reddy Dwarampudi ,&nbsp;Qingqi Yuan ,&nbsp;Alfonso Enrique Martinez-Nunez ,&nbsp;Julia Choi ,&nbsp;Kara A. Johnson ,&nbsp;Coralie de Hemptinne ,&nbsp;Joshua K. Wong","doi":"10.1016/j.prdoa.2024.100288","DOIUrl":"10.1016/j.prdoa.2024.100288","url":null,"abstract":"<div><h3>Background</h3><div>Fatigue is a prevalent yet under-recognized non-motor symptom (NMS) of Parkinson’s disease (PD), significantly impacting patients’ quality of life. Despite its clinical importance, the relationship between fatigue and other motor and non-motor symptoms remains poorly understood. Its frequent co-occurrence with other NMS further complicates both diagnosis and management, often leading to underdiagnosis and suboptimal treatment. This gap in understanding is largely due to the limited exploration of fatigue in PD.</div></div><div><h3>Objective</h3><div>This study aimed to evaluate the prevalence of fatigue at baseline and up to 10 years after symptom onset in a large, well-characterized PD cohort (PPMI) and to explore its associations with other non-motor symptoms (NMS). By providing insights into the prevalence and correlations of fatigue, our goal is to highlight the need for early identification and management, guiding future research efforts.</div></div><div><h3>Methods</h3><div> <!-->We conducted a retrospective study using the PPMI database. Fatigue was assessed using item 1.13 of the Movement Disorders Society Unified Parkinson’s Disease Rating Scale. Logistic regression was used to analyze the impact of different variables on fatigue, while point-biserial correlation analysis gauged the relationship between continuous variables and fatigue.</div></div><div><h3>Results</h3><div>At baseline study visit, 52% (575) of patients reported experiencing fatigue, with 9% reporting moderate to severe fatigue early in the disease course. Higher scores on several scales were significantly associated with an increased risk of fatigue, though most associations were weak. Significant associations included the REM Sleep Behavioral Disorder Questionnaire (OR: 1.09, 95% CI: 1.06–1.11), Geriatric Depression Scale (OR: 1.07, 95% CI: 1.03–1.11), State-Trait Anxiety Inventory (OR: 1.01, 95% CI: 1.00–1.02), SCOPA-Autonomic Dysfunction (OR: 1.05, 95% CI: 1.03–1.06), Epworth Sleepiness Scale (OR: 1.06, 95% CI: 1.04–1.08), and Apathy (OR: 2.90, 95% CI: 2.4–3.5).</div></div><div><h3>Conclusion</h3><div>Over half of patients reported fatigue at baseline, underscoring its significant prevalence early in PD. The predominantly weak associations with other NMS highlight the necessity for comprehensive patient screening and targeted interventions, as addressing one NMS may not effectively alleviate others.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"11 ","pages":"Article 100288"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142705956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Japanese longitudinal biomarker study in progressive supranuclear palsy and corticobasal degeneration: Clinical features of the first registered patients and short-term follow-up analysis","authors":"Hiroshi Takigawa ,&nbsp;Ritsuko Hanajima ,&nbsp;Ikuko Aiba ,&nbsp;Takayoshi Shimohata ,&nbsp;Takahiko Tokuda ,&nbsp;Mitsuya Morita ,&nbsp;Osamu Onodera ,&nbsp;Shigeo Murayama ,&nbsp;Kazuko Hasegawa ,&nbsp;Aya M. Tokumaru ,&nbsp;Hisanori Kowa ,&nbsp;Masato Kanazawa ,&nbsp;Tameto Naoi ,&nbsp;Kenji Nakashima ,&nbsp;Takeshi Ikeuchi ,&nbsp;JALPAC study group","doi":"10.1016/j.prdoa.2024.100279","DOIUrl":"10.1016/j.prdoa.2024.100279","url":null,"abstract":"<div><h3>Introduction</h3><div>Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) manifest with variable clinical features. We initiated a multicenter prospective registry study—the Japanese Longitudinal Biomarker Study in PSP and CBD—in November 2014 at 45 Japanese institutions to collect clinical information and biological samples to elucidate the natural courses and diagnostic biomarkers of PSP/CBD.</div></div><div><h3>Methods</h3><div>Initial symptoms, clinical features, and scores (Progressive Supranuclear Palsy Rating Scale [PSPRS], Barthel Index, Mini-Mental State Examination, and Frontal Assessment Battery) of patients clinically diagnosed with PSP/corticobasal syndrome (CBS) at the first registration were analyzed. PSPRS score progression in the initial 8 years and predictive factors were examined.</div></div><div><h3>Results</h3><div>As of October 2022, first registration had been conducted for 349 patients—57 with probable/possible Richardson’s syndrome (RS), 133 with possible CBS, 41 with overlapping CBS and PSP criteria (RS/CBS group), 20 with PSP subtypes other than RS, and 98 who did not fulfill the PSP or CBS criteria. Among the RS, CBS, and RS/CBS groups, the RS group exhibited the best scores. Initial symptoms of personality change and asymmetric onset were correlated with the total PSPRS score. The average PSPRS score increment by the second registration (n = 116 patients) was 11.8 in all three groups, and progression was correlated with cognitive dysfunction. Seventy patients died during the study period. The 5-year survival rate from onset was approximately 90 %.</div></div><div><h3>Conclusion</h3><div>There were fewer severe clinical features in the RS group than in the CBS group. Cognitive dysfunction may be important in predicting clinical severity and disease progression.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"11 ","pages":"Article 100279"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142560754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dystonia: A novel sign of the Smith-Magenis syndrome – A three-case report","authors":"Lukáš Kunc ,&nbsp;Petra Havránková ,&nbsp;Matěj Škorvánek ,&nbsp;Iva Příhodová ,&nbsp;Kamila Poláková ,&nbsp;Lenka Nosková ,&nbsp;Markéta Tesařová ,&nbsp;Tomáš Honzík ,&nbsp;Michael Zech ,&nbsp;Robert Jech","doi":"10.1016/j.prdoa.2024.100267","DOIUrl":"10.1016/j.prdoa.2024.100267","url":null,"abstract":"","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"11 ","pages":"Article 100267"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000380/pdfft?md5=bfde844c2a7a4800a64e5a7faa6d7c55&pid=1-s2.0-S2590112524000380-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141963827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: Considerations for initiation and maintenance","authors":"Victor S.C. Fung ,&nbsp;Jason Aldred ,&nbsp;Martha P. Arroyo ,&nbsp;Filip Bergquist ,&nbsp;Agnita J.W. Boon ,&nbsp;Manon Bouchard ,&nbsp;Sarah Bray ,&nbsp;Sara Dhanani ,&nbsp;Maurizio F. Facheris ,&nbsp;Nahome Fisseha ,&nbsp;Eric Freire-Alvarez ,&nbsp;Robert A. Hauser ,&nbsp;Anna Jeong ,&nbsp;Jia Jia ,&nbsp;Pavnit Kukreja ,&nbsp;Michael J. Soileau ,&nbsp;Amy M. Spiegel ,&nbsp;Saritha Talapala ,&nbsp;Arjun Tarakad ,&nbsp;Enrique Urrea-Mendoza ,&nbsp;Rajesh Pahwa","doi":"10.1016/j.prdoa.2024.100239","DOIUrl":"10.1016/j.prdoa.2024.100239","url":null,"abstract":"<div><h3>Background</h3><p>As Parkinson's disease (PD) advances, management is challenged by an increasingly variable and inconsistent response to oral dopaminergic therapy, requiring special considerations by the provider. Continuous 24 h/day subcutaneous infusion of foslevodopa/foscarbidopa (LDp/CDp) provides steady dopaminergic stimulation that can reduce symptom fluctuation.</p></div><div><h3>Objective</h3><p>Our aim is to review the initiation, optimization, and maintenance of LDp/CDp therapy, identify possible challenges, and share potential mitigations.</p></div><div><h3>Methods</h3><p>Review available LDp/CDp clinical trial data for practical considerations regarding the management of patients during LDp/CDp therapy initiation, optimization, and maintenance based on investigator clinical trial experience.</p></div><div><h3>Results</h3><p>LDp/CDp initiation, optimization, and maintenance can be done without hospitalization in the clinic setting. Continuous 24 h/day LDp/CDp infusion can offer more precise symptom control than oral medications, showing improvements in motor fluctuations during both daytime and nighttime hours. Challenges include infusion-site adverse events for which early detection and prompt management may be required, as well as systemic adverse events (eg, hallucinations) that may require adjustment of the infusion rate or other interventions. A learning curve should be anticipated with initiation of therapy, and expectation setting with patients and care partners is key to successful initiation and maintenance of therapy.</p></div><div><h3>Conclusion</h3><p>Continuous subcutaneous infusion of LDp/CDp represents a promising therapeutic option for individuals with PD. Individualized dose optimization during both daytime and nighttime hours, coupled with patient education, and early recognition of certain adverse events (plus their appropriate management) are required for the success of this minimally invasive and highly efficacious therapy.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100239"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000082/pdfft?md5=7aba3868ba6c88b9395531d46e1ba602&pid=1-s2.0-S2590112524000082-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139821206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of axial postural abnormalities in parkinsonism disorders: A systematic review of pharmacological, rehabilitative and surgical interventions","authors":"Marialuisa Gandolfi ,&nbsp;Christian Geroin ,&nbsp;Gabriele Imbalzano ,&nbsp;Serena Camozzi ,&nbsp;Zoe Menaspà ,&nbsp;Michele Tinazzi ,&nbsp;Carlo Alberto Artusi","doi":"10.1016/j.prdoa.2024.100240","DOIUrl":"10.1016/j.prdoa.2024.100240","url":null,"abstract":"<div><p>Axial postural abnormalities (PA) are frequent, highly disabling, and drug-refractory motor complications affecting patients with Parkinson’s disease (PD) or atypical parkinsonism. Over the past few years, advances have been reached across diagnosis, assessment, and pathophysiological mechanisms of PA. Nonetheless, their management remains a challenge, and these disturbances are generally overlooked by healthcare professionals, potentially resulting in their worsening and impact on patients’ disabilities. From shared consensus-based assessment and diagnostic criteria, PA calls for interdisciplinary management based on the complexity and multifactorial pathogenesis. In this context, we conducted a systematic literature review to analyze the available pharmacological and non-pharmacological treatment options for PA in PD according to the new expert-based classification of axial PA in Parkinsonism. Different multidisciplinary approaches, including dopaminergic therapy adjustment, physiotherapy, botulinum toxin injection, and deep brain stimulation, can improve PA depending on its type and severity. An early, interdisciplinary approach is recommended in PD patients to manage PA.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100240"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000094/pdfft?md5=b64a9296fddf6d5c57cb97ccc5634bb0&pid=1-s2.0-S2590112524000094-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140272859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}